90 research outputs found
Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old
Š 2004 by the Infectious Diseases Society of America. All rights reserved.A phase 2 evaluation of live attenuated parainfluenza type 3 (PIV3)âcold passage mutant 45 (cp45) vaccine was conducted in 380 children 6â18 months old; 226 children (59%) were seronegative for PIV3. Of the 226 seronegative children, 114 received PIV3-cp45 vaccine, and 112 received placebo. No significant difference in the occurrence of adverse events (i.e., runny nose, cough, or temperature 38°C) was noted during the 14 days after vaccination. There was no difference between groups in the occurrence of acute otitis media or serous otitis media. Paired serum samples were available for 109 of the seronegative vaccine recipients and for 110 of the seronegative placebo recipients; 84% of seronegative vaccine recipients developed a 4-fold increase in antibody titers. The geometric mean antibody titer after vaccination was 1:25 in the vaccine group and <1:4 in the placebo group. PIV3-cp45 vaccine was safe and immunogenic in seronegative children and should be evaluated for efficacy in a phase 3 field trial.Robert B. Belshe, Frances K. Newman, Theodore F. Tsai, Ruth A. Karron, Keith Reisinger, Don Roberton, Helen Marshall, Richard Schwartz, James King, Frederick W. Henderson, William Rodriguez, Joseph M. Severs, Peter F. Wright, Harry Keyserling, Geoffrey A. Weinberg, Kenneth Bromberg, Richard Loh, Peter Sly, Peter McIntyre, John B. Ziegler, Jill Hackell, Anne Deatly, Alice Georgiu, Maribel Paschalis, Shin-Lu Wu, Joanne M. Tatem, Brian Murphy and Edwin Anderso
A community-based lifestyle and weight loss intervention promoting a Mediterranean-style diet pattern evaluated in the stroke belt of North Carolina: the Heart Healthy Lenoir Project
Abstract
Background
Because residents of the southeastern United States experience disproportionally high rates of cardiovascular disease (CVD), it is important to develop effective lifestyle interventions for this population.
Methods
The primary objective was to develop and evaluate a dietary, physical activity (PA) and weight loss intervention for residents of the southeastern US. The intervention, given in eastern North Carolina, was evaluated in a 2Ă year prospective cohort study with an embedded randomized controlled trial (RCT) of a weight loss maintenance intervention. The intervention included: Phase I (months 1ââŹâ6), individually-tailored intervention promoting a Mediterranean-style dietary pattern and increased walking; Phase II (months 7ââŹâ12), option of a 16-week weight loss intervention for those with BMIââŹâ°Ă˘â°ÂĽĂ˘âŹâ°25Ă kg/m2 offered in 2 formats (16 weekly group sessions or 5 group sessions and 10 phone calls) or a lifestyle maintenance intervention; and Phase III (months 13ââŹâ24), weight loss maintenance RCT for those losingââŹâ°Ă˘â°ÂĽĂ˘âŹâ°8 lb with all other participants receiving a lifestyle maintenance intervention. Change in diet and PA behaviors, CVD risk factors, and weight were assessed at 6, 12, and 24Ă month follow-up.
Results
Baseline characteristics (NââŹâ°=ââŹâ°339) were: 260 (77Ă %) females, 219 (65Ă %) African Americans, mean age 56Ă years, and mean body mass index 36Ă kg/m2. In Phase I, among 251 (74Ă %) that returned for 6Ă month follow-up, there were substantial improvements in diet score (4.3 units [95Ă % CI 3.7 to 5.0]), walking (64Ă min/week [19 to 109]), and systolic blood pressure (âËâ6.4Ă mmHg [âËâ8.7 to âËâ4.1]) that were generally maintained through 24Ă month follow-up. In Phase II, 138 (57 group only, 81 group/phone) chose the weight loss intervention and at 12Ă months, weight change was: âËâ3.1Ă kg (âËâ4.9 to âËâ1.3) for group (NââŹâ°=ââŹâ°50) and âËâ2.1Ă kg (âËâ3.2 to âËâ1.0) for group/phone combination (NââŹâ°=ââŹâ°75). In Phase III, 27 participants took part in the RCT. At 24Ă months, weight loss was âËâ2.1Ă kg (âËâ4.3 to 0.0) for group (NââŹâ°=ââŹâ°51) and âËâ1.1Ă kg (âËâ2.7 to 0.4) for combination (NââŹâ°=ââŹâ°72). Outcomes for African American and whites were similar.
Conclusions
The intervention yielded substantial improvement in diet, PA, and blood pressure, but weight loss was modest.
Trial registration
clinicaltrials.gov Identifier:
NCT0143348
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trialâ
Aim High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies targeting HDL have failed to show benefits vs. placebo. Objective: To investigate the effects of an HDL-mimetic agent on atherosclerosis by intravascular ultrasonography (IVUS) and quantitative coronary angiography (QCA). Design and setting A prospective, double-blinded, randomized trial was conducted at 51 centres in the USA, the Netherlands, Canada, and France. Intravascular ultrasonography and QCA were performed to assess coronary atherosclerosis at baseline and 3 (2â5) weeks after the last study infusion. Patients Five hundred and seven patients were randomized; 417 and 461 had paired IVUS and QCA measurements, respectively. Intervention Patients were randomized to receive 6 weekly infusions of placebo, 3 mg/kg, 6 mg/kg, or 12 mg/kg CER-001. Main outcome measures The primary efficacy parameter was the nominal change in the total atheroma volume. Nominal changes in per cent atheroma volume on IVUS and coronary scores on QCA were also pre-specified endpoints. Results: The nominal change in the total atheroma volume (adjusted means) was â2.71, â3.13, â1.50, and â3.05 mm3 with placebo, CER-001 3 mg/kg, 6 mg/kg, and 12 mg/kg, respectively (primary analysis of 12 mg/kg vs. placebo: P = 0.81). There was also no difference among groups for the nominal change in per cent atheroma volume (0.02, â0.02, 0.01, and 0.19%; nominal P = 0.53 for 12 mg/kg vs. placebo). Change in the coronary artery score was â0.022, â0.036, â0.022, and â0.015 mm (nominal P = 0.25, 0.99, 0.55), and change in the cumulative coronary stenosis score was â0.51, 2.65, 0.71, and â0.77% (compared with placebo, nominal P = 0.85 for 12 mg/kg and nominal P = 0.01 for 3 mg/kg). The number of patients with major cardiovascular events was 10 (8.3%), 16 (13.3%), 17 (13.7%), and 12 (9.8%) in the four groups. Conclusion: CER-001 infusions did not reduce coronary atherosclerosis on IVUS and QCA when compared with placebo. Whether CER-001 administered in other regimens or to other populations could favourably affect atherosclerosis must await further study. Name of the trial registry: Clinicaltrials.gov; Registry's URL: http://clinicaltrials.gov/ct2/show/NCT01201837?term=cer-001&rank=2; Trial registration number: NCT01201837
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trialâ
Aim High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies targeting HDL have failed to show benefits vs. placebo. Objective To investigate the effects of an HDL-mimetic agent on atherosclerosis by intravascular ultrasonography (IVUS) and quantitative coronary angiography (QCA). Design and setting A prospective, double-blinded, randomized trial was conducted at 51 centres in the USA, the Netherlands, Canada, and France. Intravascular ultrasonography and QCA were performed to assess coronary atherosclerosis at baseline and 3 (2-5) weeks after the last study infusion. Patients Five hundred and seven patients were randomized; 417 and 461 had paired IVUS and QCA measurements, respectively. Intervention Patients were randomized to receive 6 weekly infusions of placebo, 3 mg/kg, 6 mg/kg, or 12 mg/kg CER-001. Main outcome measures The primary efficacy parameter was the nominal change in the total atheroma volume. Nominal changes in per cent atheroma volume on IVUS and coronary scores on QCA were also pre-specified endpoints. Results The nominal change in the total atheroma volume (adjusted means) was â2.71, â3.13, â1.50, and â3.05 mm3 with placebo, CER-001 3 mg/kg, 6 mg/kg, and 12 mg/kg, respectively (primary analysis of 12 mg/kg vs. placebo: P = 0.81). There was also no difference among groups for the nominal change in per cent atheroma volume (0.02, â0.02, 0.01, and 0.19%; nominal P = 0.53 for 12 mg/kg vs. placebo). Change in the coronary artery score was â0.022, â0.036, â0.022, and â0.015 mm (nominal P = 0.25, 0.99, 0.55), and change in the cumulative coronary stenosis score was â0.51, 2.65, 0.71, and â0.77% (compared with placebo, nominal P = 0.85 for 12 mg/kg and nominal P = 0.01 for 3 mg/kg). The number of patients with major cardiovascular events was 10 (8.3%), 16 (13.3%), 17 (13.7%), and 12 (9.8%) in the four groups. Conclusion CER-001 infusions did not reduce coronary atherosclerosis on IVUS and QCA when compared with placebo. Whether CER-001 administered in other regimens or to other populations could favourably affect atherosclerosis must await further study. Name of the trial registry: Clinicaltrials.gov; Registry's URL: http://clinicaltrials.gov/ct2/show/NCT01201837?term=cer-001&rank=2; Trial registration number: NCT0120183
Lista das espĂŠcies de aranhas (Arachnida, Araneae) do estado do Rio Grande do Sul, Brasil
A Review of the Occurrence of Bats (Chiroptera) on Islands in the North East Atlantic and on North Sea Installations
The bats recorded from Iceland, the Faroe Islands, the Shetland Islands, the Orkney Islands, and North Sea installations are reviewed to the end of 2012. In total 12 species have been positively identified, while a considerable proportion of all records are sightings of unidentified bats. Eight of the species are European in origin and four originate from the New World. The largest number of species (8) has been recorded in Iceland, but the greatest number of individuals (180) has been found in Orkney. The bat invasion on the Faroe Islands in 2010 is without precedence, when 70 observations of a minimum of 45 individuals were noted. Most bat observations in the study area occurred in the autumn, with fewer in the spring. Most observations were of single animals, but there were also sightings of up to 12 individuals. There has been a marked increase in bat records in the past three decades. We discuss whether this is a real increase, or due to improved communications, increased public awareness, increased shipping, changes in weather patterns and/or the effects of climate change. All factors appear to be involved.Š Museum and Institute of Zoology PAS. The attached document is the author(âsâ) final accepted/submitted version of the journal article. You are advised to consult the publisherâs version if you wish to cite from it
The Key Indicator Method for Manual Handling Operations (KIM-MHO) - evaluation of a new method for the assessment of working conditions within a cross-sectional study
Using a multilocus phylogeny to test morphology-based classifications of Polystichum (Dryopteridaceae), one of the largest fern genera
Recommended from our members
Comparison of five ELISA assays for IgG antibody against coxsackievirus B1
Enterovirus type and group specificities of five different IgG ELISA methods were compared, using neutralization titration tests as an indicator of the presence or absence of antibodies to coxsackie B (CB) viruses. One of the ELISA assays was a "standard" IgG assay, where the solid phase was coated directly with the purified virus, followed by incubations with human serum, biotinylated anti-human-IgG, streptavidin-peroxidase, and the substrate/chromogen. In a modified standard assay, blocking of common epitopes was attempted by incubating the CB1 virus antigen on the solid phase with a rabbit antiserum to CB5 before the human serum was added. In another modification the serum dilution buffer contained heat-denatured heterologous enteroviruses in an attempt to consume human antibodies reacting with common epitopes. In one assay the purified CB1 virus was captured by purified horse anti-CB1 IgG on the solid phase, before incubation with human serum. In the last of the five assays the serum specimen was incubated with CB1 virus (in the liquid phase) before the virus or virus-antibody complex was captured with purified horse anti-CB1-IgG. Reactions against common antigens dominated in the first three assays. The antigen-capture assay appeared to be at least predominantly type specific. Our data indicate that the liquid-phase assay may be type specific, but more studies are needed. The method of virus purification was critical for the type specificity of the antigen-capture and liquid-phase assays
- âŚ